BRIEF-Merck's phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone

Mon Apr 25, 2016 3:17am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 25 (Reuters) - Merck & Co Inc

* Says phase iii tailor landmark study demonstrates significant benefits of erbitux in combination with FOLFOX over FOLFOX alone

* Merck will work with relevant authorities to make Erbitux available for patients in China as a first-line treatment as soon as possible

* Phase iii tailor study met its primary endpoint of significantly increasing survival in patients with ras wild-type metastatic colorectal cancer

* Safety profile of Erbitux in tailor clinical trial was manageable,similar to observed in other trials, with no unexpected safety findings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)